hwa 138 has been researched along with Blood Coagulation Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahrami, S; Leichtfried, G; Redl, H; Schlag, G; Shiga, H; Yao, YM | 1 |
| Bahrami, S; Buurman, WA; Redl, H; Schlag, G | 1 |
2 other study(ies) available for hwa 138 and Blood Coagulation Disorders
| Article | Year |
|---|---|
Comparison of the efficacy of pentoxifylline and albifyllin (HWA 138) on endotoxin-induced cytokine production, coagulation disturbances, and mortality.
Topics: Animals; Antithrombin III; Blood Coagulation Disorders; Bronchodilator Agents; Cytokines; Dose-Response Relationship, Drug; Endotoxins; Leukocytes; Male; Pentoxifylline; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 1996 |
Influence of the xanthine derivate HWA 138 on endotoxin-related coagulation disturbances: effects in non-sensitized vs D-galactosamine sensitized rats.
Topics: Animals; Antithrombin III; Blood Coagulation Disorders; Blood Glucose; Fibrinogen; Galactosamine; Hematologic Tests; Immunization; In Vitro Techniques; Leukocyte Count; Lipopolysaccharides; Male; Partial Thromboplastin Time; Pentoxifylline; Platelet Count; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 1992 |